Watch RVPH. Know when insiders buy.
One email the day a filing lands. Free.
RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.
0.35
−0.04 −9.13%
USD · close Nov 13
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$13MNET CASH —52W 0.33 – 14.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.6M | −$2.4M | — | -0.19 | −$2.1M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$3.3M | −$3.2M | — | -0.46 | −$3.8M | — | — | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.6M | −$3.4M | — | -5.19 | −$5.8M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$4M | −$4M | — | -0.06 | −$5.6M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$6.1M | −$6.1M | — | -2.40 | −$5M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$6.5M | −$6.4M | — | -2.61 | −$8.2M | — | — | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.3M | −$6.3M | — | -16.98 | −$9.1M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$8.5M | −$8.4M | — | -0.25 | −$4.2M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$8.1M | −$7.9M | — | -0.26 | −$8.5M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$7.9M | −$7.4M | — | -0.25 | −$11.7M | — | — | May 15 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.6M | −$9.4M | — | -0.33 | −$8.9M | — | — | Apr 3 |
| Q3 2023 · Sep 30 | — | — | — | −$11.6M | −$11.3M | — | -0.48 | −$6.2M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$20.2M | −$19.9M | — | -5.48 | −$24.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$30.8M | −$29.9M | — | -17.73 | −$33.5M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$39.5M | −$39.3M | — | -1.65 | −$28.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$28.2M | −$28.3M | — | -1.45 | −$19M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$10.1M | −$8.5M | — | -0.58 | −$10.7M | — | — | — | — |
| FY2021 · to Dec 13 | — | — | −$10.1M | −$8.5M | — | -0.58 | — | — | — | — | — |
Every number comes from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.